Alfred C. Server was a partner in the Technology Transactions and Licensing Practice Group with WilmerHale LLP from 1993 until 2012. He received an AB degree, summa cum laude, from Princeton University, where he was elected to Phi Beta Kappa; he also holds a JD from Harvard Law School and an MD and a PhD (neurological sciences) from Stanford University. His medical training includes a prestigious internship at Peter Bent Brigham Hospital (a predecessor of Brigham and Women’s Hospital), a neurology residency at Johns Hopkins Hospital, and post-doctoral fellowships in neurovirology, genetics, and molecular biology at Johns Hopkins University, Harvard University and the Massachusetts General Hospital. Dr. Server was also a founder and the research director of a biotechnology company.
At WilmerHale, Dr. Server represented the firm’s clients in some of the most significant and highly regarded strategic alliance transactions in the lifesciences industry, including Incyte Corporation’s recent $2 billion licensing deals with Novartis and Eli Lilly and Company relating to the development and commercialization of drug candidates for the treatment of cancer and inflammation.
Dr. Server was also involved in the establishment of The SNP Consortium, a nonprofit organization made up of 10 of the world’s leading pharmaceutical companies and a British charity. The consortium was established to identify and develop a map of genetic variation in the human genome, which has been made publicly available.
Dr. Server recently had an article published in the John Marshall Review of Intellectual Property Law entitled "Application of the Hatch-Waxman Act's Safe Harbor Provision following Momenta."